Territorial Availability: Available through Bertin Technologies only in France
- Synonyms
- 1,4-dihydro-1-[(4-methoxyphenyl)methyl]-4-oxo-3-quinolinecarboxylic acid
- Correlated keywords
- neurosciences Alzheimer’s diseases nootropics receptors agonists research positives allosteric modulators M1 M 1 acetylcholine mAChR m AChR dose-dependently doses dependently dependents Alzheimers activates potentiations cells inflections points agonisms antagonisms brains penetrations firing rates medials prefrontal pre-frontal pre frontals cortex neurons in vivo rats scopolamine-induced scopolamine induced induces memory deficits contextual fears conditioning spontaneous alternations tasks mice impairments reversals learning mouse models performances activators muscarinic potentiators
- Product Overview:
BQCA is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor (mAChR), as it dose-dependently reduces the concentration of acetylcholine required to activate the M1 receptor.{25275} The effective range for potentiation of M1 in cells by BQCA is 0.1 to 100 ?M with an inflection point value of 845 nM when 3 nM acetylcholine is used.{25275} BQCA displays no potentiation, agonism, or antagonism at other mAChRs at concentrations up to 100 ?M.{25275} It has excellent brain penetration and increases the firing rate of medial prefrontal cortex neurons in vivo in rats.{25277} BQCA prevents scopolamine-induced memory deficits in both contextual fear conditioning and a spontaneous alternation task in mice.{25275,25278} It also restores impairment in reversal learning in a mouse model of Alzheimer’s disease and improves memory performance in rats.{25277,25279}
Cayman Chemical’s mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.
Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.
Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.
Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.
Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009
Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.